Drug intelligence / Profile preview

AP305

Development stage: Preclinical
Lead developer: Alebund Pharmaceuticals
Modality: Small Molecules

Overview

AP305 is a small molecule drug developed by Shanghai Alebund Pharmaceuticals Co., Ltd. It functions as an inhibitor of Complement factor B (CFB). The drug is currently in preclinical development, with its primary indication being IgA Glomerulonephritis, an immune system and urogenital disease.

Targets

CFB (Complement Factor B)

Beyond the preview

Go deeper on AP305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP305.

Explore the full profile